Markets:

Overview

News

Currencies

International

Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

10.46 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Vir Biotechnology Ranked the Fastest-Growing Company in North America on the 2022 Deloitte Technology Fast 500™

November 16, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Don't Use These 5 Non-Cost Effective COVID Treatments Including Antivirals From Merck and Gilead, Britain's NICE Says ↗

November 16, 2022

Via Benzinga

FDA Moves Step Closer For Opioid Overdose Medication Access, Says Certain Naloxone Products Can Potentially Be Used In OTC Setting ↗

November 15, 2022

Via Benzinga

Data From Multiple Ongoing Trials Of Vir Biotech's HBV Therapies Show Promising Action ↗

November 07, 2022

Via Benzinga

Why Vir Biotechnology Jumped Nearly 19% Today ↗

November 04, 2022

A COVID-19 partnership with a major drugmaker is producing more fruit than expected.

Via The Motley Fool

Vir Biotech Secures US Government Contract For Influenza & Other Infectious Disease Candidates ↗

October 04, 2022

Via Benzinga

This Hepatitis Stock Has 'Multiple Paths To Value Creation,' Expects To Double, Bullish Analyst Predicts ↗

September 14, 2022

Via Benzinga

Why MediaAlpha Shares Jumped Around 30%; Here Are 112 Biggest Movers From Friday ↗

November 07, 2022

Gainers

Via Benzinga

Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection

November 06, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

November 04, 2022

Gainers

Via Benzinga

What 5 Analyst Ratings Have To Say About Vir Biotechnology ↗

November 04, 2022

Over the past 3 months, 5 analysts have published their opinion on Vir Biotechnology (NASDAQ:VIR) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a...

Via Benzinga

Vir Obliterates Quarterly Sales Expectations As Covid Drug Delivers Triple-Digit Growth ↗

November 04, 2022

Sales of Vir Biotechnology and GSK's Covid antibody almost tripled sales estimates.

Via Investor's Business Daily

Block, MasTec, Universal Display And Some Other Big Stocks Moving Higher On Friday ↗

November 04, 2022

U.S. stocks traded higher, with the Dow Jones gaining more than 400 points on Friday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Why Yelp Shares Are Trading Lower By 15%? Here Are 86 Stocks Moving In Friday's Mid-Day Session ↗

November 04, 2022

Gainers

Via Benzinga

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 03, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2022

October 31, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2022 Financial Results on November 3, 2022

October 28, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Earnings Scheduled For November 3, 2022 ↗

November 03, 2022

Companies Reporting Before The Bell • Hyatt Hotels (NYSE:H) is estimated to report quarterly earnings at $0.28 per share on revenue of $1.45 billion.

Via Benzinga

Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny ↗

October 20, 2022

Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to...

Via Benzinga

This Addiction Drug Shows Some Potential Against Long COVID Symptoms ↗

October 19, 2022

Researchers are working on cures for long COVID. With some success, naltrexone has been used to treat pain, fatigue, and brain fog months after a coronavirus infection.

Via Benzinga

Vir Biotechnology Announces First Patient Dosed in Groundbreaking Phase 2 Trial of VIR-2482 for Antibody Prophylaxis of Influenza A

October 18, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

Vir Biotechnology to Participate in the H. C. Wainwright 3rd Annual Hepatitis B Virus (HBV) Conference

October 11, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

The Next Pandemic? Vir Biotechnology Just Signed A $1 Billion Deal To Work On It ↗

October 04, 2022

BARDA will pay Vir up to $1 billion to develop its experimental treatment.

Via Investor's Business Daily

Vir Biotechnology Awarded U.S. Government Contract to Support Pandemic Preparedness for Influenza and Other Infectious Disease Threats

October 04, 2022

From Vir Biotechnology, Inc.

Via GlobeNewswire

3 Biotech Stocks to Buy Now for Extraordinary Gains ↗

September 20, 2022

These biotech stocks should deliver big gains to long-term investors who purchase shares at a discount during the bear market.

Via InvestorPlace

WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete ↗

September 16, 2022

Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies.

Via Benzinga

White House May Ask For $25B Emergency Funding For COVID-19, Monkeypox ↗

September 02, 2022

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022 ↗

September 14, 2022

Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low...

Via Benzinga

Landmark Drug Pricing Reform Bill Passes Congress House ↗

August 15, 2022

The U.S. House of Representatives voted 220-207 to pass new, wide-ranging legislation allowing Medicare drug price negotiations for the first time and capping seniors’ drug expenses to $2,000 per year...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗

September 09, 2022

Upgrades

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

15 16 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.